Outcome of treatment of MDR-TB or drug-resistant

patients treated with bedaquiline and delamanid :

Results from a large global cohort

Fadli
Nur Ahmad Tabri

Department of Internal Medicine

Medical Faculty
Hasanuddin University
2021
 INTRODUCTION
WHO : about half million people suffer from multidrug (MDR-) or
rifampicin-resistant (RR-) tuberculosis (TB) in 2019  38% accessed
treatment and 57% were successfully treated.

Bedaquiline (group A) and Delamanid (group C) have been recently licensed

to manage MDR- and XDR-TB  into a new WHO drug classification.

Many evidence is becoming available from experimental and observational

studies on the efficacy and effectiveness of new drugs, but their effectiveness
is still incomplete worldwide.

The aim of the study is to prospectively evaluate the effectiveness of

bedaquiline and/or delamanid containing regimens in a cohort of consecutive
TB patients treated globally.
 METHODS
Study design is observational, prospective and based on the collection
twice a year and analysis of data provided by GTN (Global Tuberculosis
Network) centres.

All consecutive patients (including children and adolescents) treated with

bedaquiline and/or delamanid were enrolled either from the beginning of
the study or from the time the drugs under study were introduced in the
respective country centre (e.g. in Mexico, Nepal, Paraguay, Spain,
Slovakia and Sudan) and data collected up to the 31st January 2021.

The information collected (from the clinical files of the participating

centres) included patient’s demographic data, bacteriological,
radiological and clinical status at diagnosis, and details on bacteriological
conversion and final treatment outcomes.
RESULTS
RESULTS
 DISCUSSION
The aim of the present study was to prospectively evaluate
the outcome of a global cohort of patients treated with
new anti-TB drugs  first global study prospectively
reporting detailed information on treatment outcomes.